Investigating biomarkers for neurological side effects in cancer treatment
Genetic Predisposition, Inflammation, and Neurodegeneration Biomarkers in Patients With Neurological Adverse Events of Immune Checkpoint Inhibitors: Correlation With Clinical Phenotypes and Outcome
This study is trying to see if certain biological markers can help explain the nerve-related side effects that cancer patients experience when treated with immune checkpoint inhibitors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Bron) |
| Trial ID | NCT05969379 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on neurological immune-related adverse events (n-irAEs) that occur in cancer patients treated with immune checkpoint inhibitors. It aims to characterize the clinical features and outcomes of these events while analyzing various biomarkers related to genetic predisposition, inflammation, and neurodegeneration. By correlating these biomarkers with clinical characteristics, the study seeks to enhance understanding of n-irAEs and their diverse manifestations.
Who should consider this trial
Good fit: Ideal candidates for this study are cancer patients who have been clinically diagnosed with neurological immune-related adverse events.
Not a fit: Patients with alternative diagnoses explaining their neurological symptoms will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification and management of neurological side effects in cancer patients undergoing immunotherapy.
How similar studies have performed: While the investigation of biomarkers in this context is emerging, similar studies have shown promise in understanding immune-related adverse events, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of n-irAEs Exclusion Criteria: * Presence of an alternative diagnosis explaining the neurological syndrome
Where this trial is running
Bron
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Hôpital neurologique Pierre Wertheimer — Bron, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.